Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

A vailable tyrosine kinase inhibitors for chronic myeloid leukemia bind in an adenosine 5′-triphosphate-binding pocket and are affected by evolving mutations that confer resistance. Rebastinib was identified as a switch control inhibitor of BCR-ABL1 and FLT3 and may be active against resistant mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge, Talpaz, Moshe, Smith, Hedy P., Snyder, David S., Khoury, Jean, Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard, Mitchell, David, Wise, Scott C., Rutkoski, Thomas J., Smith, Bryan D., Flynn, Daniel L., Kantarjian, Hagop M., Rosen, Oliver, Van Etten, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394958/
https://www.ncbi.nlm.nih.gov/pubmed/27927766
http://dx.doi.org/10.3324/haematol.2016.152710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394958/
https://www.ncbi.nlm.nih.gov/pubmed/27927766
http://dx.doi.org/10.3324/haematol.2016.152710

Ejemplares similares